The Discounted Cash Flow (DCF) valuation of Lotus Pharmaceutical Co Ltd (1795.TW) is 314.32 TWD. With the latest stock price at 215.00 TWD, the upside of Lotus Pharmaceutical Co Ltd based on DCF is 46.2%.
Based on the latest price of 215.00 TWD and our DCF valuation, Lotus Pharmaceutical Co Ltd (1795.TW) is a buy. Buying 1795.TW stocks now will result in a potential gain of 46.2%.
Range | Selected | |
WACC / Discount Rate | 4.9% - 7.1% | 6.0% |
Long-term Growth Rate | 0.0% - 1.0% | 0.5% |
Fair Price | 242.76 - 444.15 | 314.32 |
Upside | 12.9% - 106.6% | 46.2% |
(TWD in millions) | Projections | |||||
12-2024 | 12-2025 | 12-2026 | 12-2027 | 12-2028 | 12-2029 | |
Revenue | 18,584 | 21,056 | 21,450 | 21,881 | 23,549 | 25,763 |
% Growth | 10% | 13% | 2% | 2% | 8% | 9% |
Cost of goods sold | (7,660) | (8,679) | (8,841) | (9,019) | (9,707) | (10,619) |
% of Revenue | 41% | 41% | 41% | 41% | 41% | 41% |
Selling, G&A expenses | (4,130) | (4,679) | (4,767) | (4,863) | (5,234) | (5,726) |
% of Revenue | 22% | 22% | 22% | 22% | 22% | 22% |
Research & Development | (774) | (877) | (893) | (911) | (981) | (1,073) |
% of Revenue | 4% | 4% | 4% | 4% | 4% | 4% |
Net interest & other expenses | 340 | 385 | 392 | 400 | 430 | 471 |
% of Revenue | 2% | 2% | 2% | 2% | 2% | 2% |
Tax expense | (1,294) | (1,517) | (1,545) | (1,576) | (1,697) | (1,856) |
Tax rate | 20% | 21% | 21% | 21% | 21% | 21% |
Net profit | 5,066 | 5,688 | 5,795 | 5,911 | 6,362 | 6,960 |
% Margin | 27% | 27% | 27% | 27% | 27% | 27% |